Evidence map›Paper›PMID 38985249›Full record

ArticleClinical journal of gastroenterology2024

Successful intrahepatic cholangiocarcinoma conversion surgery after administration of fibroblast growth factor receptor inhibitor.

Junichi Kaneko, Ryota Kiuchi, Masaki Takinami, Ippei Ohnishi, Jun Ito, Osamu Jindo, Masafumi Nishino, Yurimi Takahashi, Takanori Yamada, Takanori Sakaguchi

Abstract readCase Reports
In one paragraph

Article in Clinical journal of gastroenterology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Junichi KanekoDepartment of Gastroenterology, Iwata City Hospital, 512-3 Ookubo, Iwata, Shizuoka, Japan. meganerock10@gmail.com.ORCID http://orcid.org/0000-0002-6637-6997
Ryota KiuchiDepartment of Gastroenterological Surgery, Iwata City Hospital, Iwata, Shizuoka, Japan.
Masaki TakinamiDepartment of Gastroenterology, Iwata City Hospital, 512-3 Ookubo, Iwata, Shizuoka, Japan.
Ippei OhnishiDivision of Pathology, Iwata City Hospital, Iwata, Shizuoka, Japan.
Jun ItoDepartment of Internal Medicine II, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.
Osamu JindoDepartment of Gastroenterological Surgery, Iwata City Hospital, Iwata, Shizuoka, Japan.
Masafumi NishinoDepartment of Gastroenterology, Iwata City Hospital, 512-3 Ookubo, Iwata, Shizuoka, Japan.
Yurimi TakahashiDepartment of Hepatology, Iwata City Hospital, Iwata, Shizuoka, Japan.
Takanori YamadaDepartment of Gastroenterology, Iwata City Hospital, 512-3 Ookubo, Iwata, Shizuoka, Japan.
Takanori SakaguchiDepartment of Gastroenterological Surgery, Iwata City Hospital, Iwata, Shizuoka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We describe a case of a 47-year-old male patient with initially unresectable intrahepatic cholangiocarcinoma of the right liver lobe with tumor thrombi extending from the right bile duct to the common and left bile ducts. Conventional chemotherapy with gemcitabine and cisplatin for 19 months resulted in progressive disease. Subsequently, a comprehensive genome profile revealed fibroblast growth factor receptor 2 rearrangement, and hence, pemigatinib administration was initiated. After 6 months of pemigatinib therapy, significant shrinking of the tumor and disappearance of the tumor thrombi in the common and left bile duct were observed. Subsequently, the patient underwent conversion surgery, resulting in successful radical resection of the tumor. The patient has been disease-free for 7 months.

Indexed as

Bile Duct NeoplasmsCholangiocarcinomaAntineoplastic AgentsBile Ducts, IntrahepaticHepatectomyHumansMaleMiddle AgedMorpholinesPyrimidinesPyrrolesReceptor, Fibroblast Growth Factor, Type 2Antineoplastic AgentsMorpholinespemigatinibPyrimidinesPyrrolesReceptor, Fibroblast Growth Factor, Type 2Biliary tract neoplasmComprehensive genome profileConversion surgeryIntrahepatic cholangiocarcinomaPemigatinib

Identifiers

PMID38985249
PMCPMC11436442

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.